Homocysteine and progression of generalized small-vessel disease :The SMART-MR study

Neurology

Volumn 82, Issue 9, 2014, Pages 777-783

  Kloppenborg, Raoul P ^a,b,e   Geerlings, Mirjam I ^e   Visseren, Frank L ^c   Mali, Willem P T M ^d   Vermeulen, M ^a   Van Der Graaf, Yolanda ^e   Nederkoorn, Paul J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Departments of Paediatric Neurology   (Netherlands)

^c Departments of Neurology Internal Medicine   (Netherlands)

^d Departments of Neurology Internal Medicine and Radiology   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE;

ADULT; ARTICLE; ATHEROSCLEROSIS; BRAIN INFARCTION; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RISK FACTOR; WHITE MATTER;

AGE FACTORS; AGED; ATROPHY; BRAIN; CEREBROVASCULAR DISORDERS; DISEASE PROGRESSION; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; KIDNEY DISEASES; MALE; MIDDLE AGED; NERVE FIBERS, MYELINATED; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS;

EID: 84895733355     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000168     Document Type: Article

References (33)

1. Silbert LC, Nelson C, Howieson DB, Moore MM, Kaye JA. Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline. Neurology 2008;71:108-113.
2. Conijn MM, Kloppenborg RP, Algra A, et al SMART Study Group. Cerebral small vessel disease and risk of death, ischemic stroke, and cardiac complications in patients with atherosclerotic disease: The Second Manifestations of ARTerial disease-Magnetic Resonance (SMART-MR) Study. Stroke 2011;42:3105-3109.
3. Wardlaw JM, Sandercock PA, Dennis MS, Starr J. Is breakdown of the blood-brain barrier responsible for lacunar stroke, leukoaraiosis, and dementia? Stroke 2003;34: 806-812.
4. Seliger SL, Longstreth WT Jr. Lessons about brain vascular disease from another pulsating organ, the kidney. Stroke 2008;39:5-6.
5. Ikram MA, Vernooij MW, Hofman A, Niessen WJ, van der Lugt A, Breteler MM. Kidney function is related to cerebral small vessel disease. Stroke 2008;39:55-61.
6. Seliger SL, Longstreth WT Jr, Katz R, et al. Cystatin C and subclinical brain infarction. J Am Soc Nephrol 2005; 16:3721-3727.
7. Kobayashi S, Ikeda T, Moriya H, Ohtake T, Kumagai H. Asymptomatic cerebral lacunae in patients with chronic kidney disease. Am J Kidney Dis 2004;44:35-41.
8. Khatri M, Wright CB, Nickolas TL, et al. Chronic kidney disease is associated with white matter hyperintensity volume: The Northern Manhattan study. Stroke 2007;38: 3121-3126.
9. Hassan A, Hunt BJ, O'Sullivan M, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 2004;127:212-219.
10. Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993;40:23023-23025.
11. Szolnoki Z. Chemical events behind leukoaraiosis: Medicinal chemistry offers new insight into a specific microcirculation disturbance in the brain (a chemical approach to a frequent cerebral phenotype). Curr Med Chem 2007;14: 1027-1036.
12. Kloppenborg RP, Nederkoorn PJ, van der Graaf Y, Geerlings MI. Homocysteine and cerebral small vessel disease in patients with symptomatic atherosclerotic disease. The SMART-MR Study. Atherosclerosis 2011;216:461-466.
13. Vermeer SE, van Dijk EJ, Koudstaal PJ, et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol 2002;51:285-289.
14. Wright CB, Paik MC, Brown TR, et al. Total homocysteine is associated with white matter hyperintensity volume: The Northern Manhattan Study. Stroke 2005;36:1207-1211.
15. Sachdev P, Parslow R, Salonikas C, et al. Homocysteine and the brain in midadult life: Evidence for an increased risk of leukoaraiosis in men. Arch Neurol 2004;61:1369-1376.
16. Seshadri S, Wolf PA, Beiser AS, et al. Association of plasma total homocysteine levels with subclinical brain injury: Cerebral volumes, white matter hyperintensity, and silent brain infarcts at volumetric magnetic resonance imaging in the Framingham Offspring Study. Arch Neurol 2008;65:642-649.
17. Narayan SK, Firbank MJ, Saxby BK, et al. Elevated plasma homocysteine is associated with increased brain atrophy rates in older subjects with mild hypertension. Dement Geriatr Cogn Disord 2011;31:341-348.
18. Geerlings MI, Appelman AP, Vincken KL, et al SMART Study Group. Brain volumes and cerebrovascular lesions on MRI in patients with atherosclerotic disease. The SMART-MR Study. Atherosclerosis 2010;210:130-136.
19. Anbeek P, Vincken KL, van Osch MJ, Bisschops RH, van der Grond J. Probabilistic segmentation of white matter lesions in MR imaging. Neuroimage 2004;21:1037-1044.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
21. Rubin DB, Schenker N. Multiple imputation in healthcare databases: An overview and some applications. Stat Med 1991;10:585-598.
22. Clarke R, Lewington S, Donald A, et al. Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies. J Cardiovasc Risk 2001;8:363-369.
23. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002;288:2015-2022.
24. The VITATOPS Trial Study Group. B Vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: A randomised, double blind, parallel, placebo-controlled trial. Lancet Neurol 2010;9:855-865.
25. Spence JD. Homocysteine-lowering therapy: A role in stroke prevention? Lancet Neurol 2007;6:830-838.
26. House AA, Eliasziw M, Cattran DC, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: A randomized controlled trial. JAMA 2010;303:1603-1609.
27. Spence JD. B vitamin therapy for homocysteine: Renal function and vitamin B12 determine cardiovascular outcomes. Clin Chem Lab Med 2013;51:633-637.
28. Yi F, Li PL. Mechanisms of homocysteine-induced glomerular injury and sclerosis. Am J Nephrol 2008;28: 254-264.
29. Ghorbanihaghjo A, Javadzadeh A, Argani H, et al. Lipoprotein (a), homocysteine, and retinal arteriosclerosis. Mol Vis 2008;14:1692-1697.
30. Wong TY, Mitchell P. Hypertensive retinopathy. N Engl J Med 2004;351:2310-2317.
31. Pantoni L. Cerebral small vessel disease: From pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010;9:689-701.
32. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 379:165-180.
33. Sundström J, Sullivan L, D'Agostino RB, et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: The Framingham Heart Study. Hypertension 2003;42:1100-1105.